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Abstract
Approximately 10-20% of children and 40% of adults with idiopathic nephrotic syndrome are steroid resistant 
and progress to end-stage renal disease requiring dialysis or renal transplantation. In these cases, renal histolo-
gy typically shows focal segmental glomerulosclerosis. Mutations in NPHS1, NPHS2, WT1, CD2AP and ACTN4 
genes located on different chromosomes, expressed by glomerular podocytes, have been identified in patients with 
steroid-resistant nephrotic syndrome. 
The authors report two cases of adolescent-onset steroid-resistant nephrotic syndrome. Both cases had similar 
clinical and histopathological manifestations, with different prognosis and evolution due to different mechanisms 
leading to proteinuria: an acquired and a genetic form. The first case, a 16 year old girl presented the onset of the 
disease with massive, generalized edema, secondary hypothyroidism and high blood pressure. Evolution was favor-
able under cyclosporine therapy. The second case, a 13-years-old adolescent girl, presented an insidious onset of 
the disease with mild edema. Genetic testing revealed a mutation in the WT1 gene. The patient developed end-stage 
kidney failure eight months after the onset of the disease and following kidney transplant had a favorable evolution. 
Histological examination of the renal biopsy specimen showed focal segmental glomerulosclerosis in both cases. 
Conclusions: Genetic forms of nephrotic syndrome do not respond to immunosuppressive therapy and may 
progress to end-stage renal disease, but after kidney transplantation relapse is not expected, in contrast to the im-
mune form. The early genetic diagnosis in steroid-resistant nephrotic syndrome is time-consuming, but is important 
for proper clinical management of the patients, prognosis and genetic counseling of the families.
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Rezumat
Autorii prezintă două cazuri de sindrom nefrotic cortico-rezistent cu debut în adolescenţă, cu manifestări 
clinice şi histopatologice similare (scleroză glomerulară focal-segmentală), dar cu mecanisme diferite de 
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Introduction
Idiopathic nephrotic syndrome (NS) de-
scribes the collection of clinical and laboratory 
findings secondary to glomerular dysfunction, 
resulting in proteinuria [1, 2]. The annual prev-
alence is 2-16/100,000 [1, 3]. The diagnostic 
criteria are massive proteinuria (>50mg/kg/day), 
generalized edema, hypoalbuminemia and hy-
perlipidemia [3, 4].
The majority of patients with NS respond to 
steroid therapy and have a good clinical prog-
nosis. Unfortunately, approximately 10-20% of 
children and 40% of adults with idiopathic NS 
are resistant to steroid treatment (SRNS) and 
progress to end-stage renal disease (ESRD) re-
quiring dialysis or renal transplantation [2-7]. In 
these cases, renal histology usually shows focal 
segmental glomerulosclerosis (FSGS) [3, 6, 7]. 
Based on etiology, two forms of SRNS are 
distinguished, an immune and a genetic form, 
with different treatments, thus a correct clinical 
diagnosis becomes essential [4, 6, 8]. In genetic 
forms of SRNS were identified so far mutations 
in more than 20 genes, most of which encode 
podocyte proteins. The most frequently mutated 
genes are NPHS2, WT1, and NPHS1 [5, 6, 8-10].
We report two cases of steroid-resistant ne-
phrotic syndrome with FSGS in female adoles-
cents. Both cases had similar clinical and his-
topathologic manifestations, but two different 
mechanisms leading to proteinuria: an acquired 
and a genetic form, and therefore a very different 
prognosis and evolution.
Patients and observation
The first patient, a 16 year old WT1negative 
girl, with no significant medical history, was ad-
mitted to hospital with a seven week history of 
edema. Physical examination revealed moderate 
periorbital and significant lower leg edema. The 
24 hour ambulatory blood pressure monitoring 
showed high blood pressure (above the 95th per-
centile). 
Laboratory data (presented in Table I) re-
vealed nephrotic-range proteinuria without hae-
maturia, hypoproteinemia and hyperlipidemia. 
Blood urea nitrogen, creatinine, electrolytes, im-
munogram and complementemia were normal, 
but secondary hypothyroidism was observed: 
FT3 1.04 pg/ml (reference range: 1.4-4.7 pg/ml), 
FT4 0.45 ng/dl (reference range: 0.8-2.2 ng/dl), 
and TSH 45 IU/ml (reference range: 0.4-4 IU/
ml).
Based on clinical and laboratory data, the di-
agnosis of nephrotic syndrome was established 
and prednisone therapy was initiated (60 mg/
m2). The evolution under steroid treatment was 
unfavorable with persistent massive proteinuria 
(2.9-5.8 g/24 hours) (Figure 1).
producere a proteinuriei: o formă dobândită şi una genetică, având astfel prognostic şi evoluţie diferită. Primul 
caz, o adolescentă de 16 ani prezintă debutul bolii brusc cu edeme masive, generalizate, cu răspuns favorabil 
la tratamentul cu ciclosporină. A doua pacientă, o adolescentă de 13 ani, a prezentat sindrom nefrotic cortico-
rezistent cu debut insidios cu edeme uşoare. În acest caz testarea genetică a evidenţiat o mutaţie în gena WT1, iar 
evoluţia a fost rapidă (în 8 luni) către insuficienţă renală terminală, dar cu evoluţie şi prognostic favorabil după 
transplant renal. Concluzii: Formele genetice ale sindromului nefrotic nu răspund la tratamentul imunosupresiv şi 
pot evolua către boală renală terminală, dar după transplant recăderea este puţin probabilă, în contrast cu formele 
imune. Diagnosticul genetic precoce în sindromul nefrotic cortico-rezistent este important pentru managementul 
optim al pacienţilor, precizarea prognosticului, respectiv pentru  consilierea genetică a familiei.
Cuvinte cheie: sindrom nefrotic cortico-rezistent; adolescent; WT1; FSGS
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Following corticotherapy our patient pre-
sented side effects, showing Cushingoid ap-
pearance, hirsutism, striae on the abdomen and 
thighs, high BP (152/94 mmHg) and  obesity 
(weight 86 kg, BMI: 32.6 kg/m2). The diagnosis 
of SRNS emerged as no remission was observed 
after 4 weeks of prednisone therapy and three 
intravenous pulses of methylprednisolone, so 
corticotherapy was suspended. Cyclophospha-
mide treatment (3mg/kg, for 8 weeks) was in-
troduced, but no remission was observed, than, 
subsequently cyclosporine therapy was initiated. 
In the meantime renal biopsy and genetic testing 
were performed. 
Renal biopsy, performed at 10 months after 
the diagnosis of the disease, showed focal seg-
mental glomerulosclerosis (FSGS). It reported 
both focal (6 glomeruli affected) and segmen-
tal (only the perihilar portion of the affected 
glomerulus was sclerotic in 1 juxtamedullary 
located glomerulus) lesions. 
The coding exons and splicing junctions 
of NPHS2 and WT1 were directly (Sanger) se-
quenced for both patients. Genomic DNA was 
isolated from peripheral blood by standard 
methods, after obtaining informed consent from 
Table I. Clinical features and laboratory data at the onset of the disease
WT1 negative (first 
patient)
WT1 positive (second 
patient)
Clinical features
Age (years) 16 13
Weight at presentation (kg) 79 36
Weight at discharge (kg) 69 35
Height (cm) 163 158
  Edema
periorbital edema moderate mild
lower leg edema significant without
Laboratory parameters
Proteinuria (g/day) 5.8-8.7 6.35-7.2
Serum protein (g/l) 46 50
Serum cholesterol (mg/dl) 227 345
Serum triglyceride (mg/dl) 181 205
the patient’s parents. Exons 1-8 of NPHS2 and 
exons 8 and 9 of WT1 with their adjacent intron-
ic junctions were analyzed by direct sequencing 
using the ABI3500 Genetic Analyzer (Applied 
Biosystems, Foster City, CA) in the genetic lab-
oratory of Ist Department of Pediatrics, Semmel-
weis University, Budapest, Hungary. Primers are 
available upon request. For the sequence analy-
sis, the Sequencher software (Gene Codes, Ann 
Arbor, MI) was used.
In this case no mutation was found, neither 
in NPHS2 and WT1, nor in the subsequently se-
quenced PAX2 gene. 
The patient’s evolution under immunosup-
pressive treatment was favorable, resulting in 
complete remission (proteinuria <150 mg/day) 
after 9 weeks of therapy. No relapse has occurred 
since, the patient being without treatment for the 
past 22 months. 
Our second case, a 13 year old WT1positive 
girl, was admitted to hospital with a four week 
history of mild eye swelling and facial puffi-
ness. In her medical history we noted an unin-
vestigated episode of edema syndrome at the age 
of seven, with spontaneous resolution. Physical 
examination revealed mild periorbital edema 
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without any extension to the legs, 
otherwise normal status with nor-
mal heart rate and blood pressure 
and a normal female phenotype. 
The main laboratory results are 
presented in table I. Based on 
these data the diagnosis of NS was 
made and corticotherapy was start-
ed, but no response was observed 
after 4 weeks. The side effects of 
corticotherapy were also noticed 
in this girl: moon face, hirsutism, 
striae, arterial hypertension 140/90 
mmHg with epistaxis and transient 
hyperglycemia (179 mg%). There-
fore, steroid treatment was discon-
tinued and cyclosporine treatment 
was started. Complementary in-
vestigations (kidney biopsy, genet-
ic test) were performed in this case 
too.
The renal biopsy, performed 
at 6 months after the diagnosis 
of the disease, also reported both 
focal (9 glomeruli affected) and 
segmental (perihilar portion of af-
fected glomerulus sclerotic in 3 
juxtamedullary located glomeruli) 
lesions. 
In both cases the interstitium 
was widened and tubular atrophy 
was observed only in the vicinity 
of the affected glomeruli. Small 
and medium-sized arteries were 
showing specific changes for hy-
pertension. Direct immunofluores-
cent staining revealed no immune 
deposits: negative for IgA, IgG, 
IgM immunoglobulins, kappa and 
lambda light chains, and Comple-
ment C4 and C1q proteins. The 
anti-C3 antibody test was weakly 
positive in arteries and glomeru-
Figure 1. Laboratory test results over time. a. Evolution of 
the urinary protein excretion – stationary in both cases under 
corticosteroid treatment. Disappearance of proteinuria in 
WT1 negative case under immunosuppressive therapy and 
in the WT1 positive case after transplantation. b. Laboratory 
investigations in dynamics in the second WT1 positive case. (CPA – 
cyclophosphamid, CyA – cyclosporine A)
a
b
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DNA sample was available from the asymptom-
atic mother. To rule out the diagnosis of Frasier 
syndrome, generated by the mutation in the WT1 
gene, a karyotype was performed, that indicated 
a female 46,XX chromosomal formula.  
In this WT1 positive patient, no changes 
in the degree of proteinuria were seen after 3 
months of cyclosporine therapy, therefore treat-
ment was discontinued.
The evolution under symptomatic therapy 
was unfavorable with high BP (180/115 mmHg) 
unresponsive to antihypertensive treatment and 
reduction of glomerular filtration rate (Figure 
1), progressing to ESRD at 8 months after the 
onset of the disease. She underwent transplanta-
tion two months later. There was no recurrence 
during the follow-up period of 14 months. 
Based on clinical and laboratory data, the 
diagnosis of steroid-resitant nephrotic syndrome 
was established in both cases; in the first case, 
an immune form, with favorable evolution under 
immunosuppressive therapy, while in the second 
case, a genetic form, with a pathogenic mutation 
in the WT1 gene, with favorable evolution after 
renal transplantation.
Discussion
 In all children with SRNS, treatment is prob-
lematic and is directed against immunological 
abnormalities. In all cases it is recommended to 
perform a renal biopsy before immunosuppres-
sive therapy. As a second-line drug, two options 
are considered: alkylating agents and calcineurin 
inhibitors. [1] The randomized controlled trials 
in children with SRNS have demonstrated that 
calcineurin inhibitors are more effective than 
placebo or no specific therapy and also alkylat-
ing agents (30-33% of patients treated with cy-
closporin obtained complete remission and 70% 
partial remission, while with cyclophosphamide 
favorable response was observed in 17-28%). 
[1, 11] 
Figure 2. Light microscopy image of renal biopsy 
specimen from the WT1 positive patient (with 
similar modifications in the first patient): a. one 
glomerulus with global sclerosis (black arrow) 
and two glomeruli with perihilar segmental 
sclerosis (white arrow) (PAS stain, x200). b. A 
glomerulus with perihilar segmental sclerosis 
(Jones-stain, x400)
lar arterioles. Electron microscopy examination 
showed diffuse effacement of the epithelial cell 
foot (podocyte) processes (Figure 2).
In case of this patient genetic testing re-
vealed a heterozygous mutation in the WT1 gene 
(c.1228+5 G>A) (Figure 3). As frequently ob-
served, the mutation is likely to be de novo, as 
the father does not carry the mutation, though no 
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In this report two cases of adolescent onset 
SRNS are presented, with two different mecha-
nisms leading to proteinuria and therefore with 
very different evolutions. Both cases presented 
primary resistance to steroid therapy. The first 
adolescent presented an acquired form of SRNS 
and FSGS, with favorable response to immuno-
suppressive therapy with a calcineurin inhibitor. 
In contrast, the second case presented an adoles-
cent onset congenital form of SRNS and FSGS, 
with no response to the corticosteroid and immu-
nosuppressive treatment and rapid progression 
towards ESRD.
Identification of a pathogenic mutation in 
a patient with SRNS has direct clinical conse-
quences, as it makes further immunosuppressive 
treatment unnecessary and the recurrence of NS 
in a kidney graft unlikely [2, 4, 9, 12-15].
In patients with SRNS, WT1 mutations can 
lead to three distinct clinical entities [2, 9, 13-
15]. 1. Denys-Drash syndrome, typically charac-
terized by the triad of infantile SRNS with male 
pseudo-hermaphroditism, diffuse mesangial 
sclerosis and Wilms tumor; this was ruled out 
by the clinical manifestations (adolescent on-
set) and the histologically evidenced FSGS. 2. 
Frasier syndrome, characterized by association 
of SRNS with male pseudohermaphroditism, ex-
cluded by normal female karyotype (46, XX). 3. 
isolated NS – as we found in our case.
The identified WT1 mutation is a frequent 
mutation in Frasier syndrome, which affects the 
Figure 3. Sequencing chromatogram of the WT1 gene in the donor splice-site of intron 
9: c.1228+5 G>A mutation in heterozygous state in the second patient
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cleavage of exon 9 [13,14]. This form of NS 
does not respond to immunosuppressive therapy 
and patients should receive symptomatic treat-
ment only. This mutation leads to several patho-
logical conditions, including renal failure in the 
second or third decade of life. In case of our sec-
ond patient the disease evolved rapidly to ESRD, 
within 8 months and as expected, no recurrence 
was seen after kidney transplantation.
The autosomal dominant transmission of 
this mutation means that the patient’s daughters 
will have a 50% risk of inheriting the mutation. 
While male descendants will have the same risk 
of inheritance, they will also show associated 
genital disorders (intersex genitalia). If these 
children then develop FSGS, their disease will 
be more severe than that of their affected parent. 
The newborn child of a woman showing a mu-
tated WT1 gene associated with isolated FSGS 
(like our patient) can develop a more severe phe-
notype, like Denysh–Drash Syndrome or Fra-
sier Syndrome [17]. If the mutation is known, 
targeted molecular prenatal diagnosis is possible 
and genetic counseling is highly recommended. 
Although the WT1 gene mutations predispose to 
Wilms tumor and gonadoblastoma, they rarely 
develop when the mutation affects the splice site 
regions [9, 13, 16, 18]. According to literature, 
the risk of nephroblastoma in our patient is 5% 
and germ cell tumors occur only in patients with 
sex reversal [18].
Because detecting a mutation in patients 
with NS decisively influences the therapeutic 
options and reduces the possibility of post trans-
plant relapses, screening for mutations in these 
genes is justified in clinical practice. If mutations 
in the WT1 gene are found in a patient with a 
female phenotype, the gender genotype must be 
investigated (thus excluding the XY genotype 
with pseudohermaphroditism) [17].
There is an urgent need to distinguish be-
tween patients who may benefit from prolonged 
immunosuppressive treatment and those who 
do not, nevertheless suffering from its side ef-
fects. In clinical practice, steroid therapy is ini-
tiated in all patients and genetic investigations 
are required only if steroid resistance is being 
observed. This initial steroid treatment can be 
avoided in patients with a family history of 
SRNS or in those who have a known causative 
mutation. In many cases, there is a tremendous 
delay between diagnosis and the request for 
genetic testing, although the genetic forms of 
SRNS should receive only symptomatic treat-
ment [11].
Conclusion
Steroid-resistant nephrotic syndrome is not 
a single entity, therefore it is important to deter-
mine and understand the underlying mechanisms 
and diseases. The genetic form of NS does not 
respond to immunosuppressive therapy and may 
progress to ESRD, but after kidney transplanta-
tion relapse is not expected, in contrast to the im-
mune form. As WT1 mutation is frequently found 
in young patients with NS, genetic screening is 
important for tumor prophylaxis, these patients 
having an increased risk to develop Wilms tumor 
or gonadoblastoma. These cases highlight the 
importance of early genetic diagnosis in SRNS. 
Although genetic testing is time-consuming, it is 
important for proper clinical management of the 
patients, prognosis and genetic counseling of the 
families.
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FSGS - focal segmental glomerulosclerosis
FT3 - free triiodothyronine
FT4 - free thyroxine
NS - nephrotic syndrome
NPHS2 - nephrosis 2, idiopathic, steroid-resis-
tant (podocin) gene
NPHS1 - nephrosis 1, congenital, Finnish type 
(nephrin) gene
SRNS - steroid resistant nephrotic syndrome
TSH - Thyroid-stimulating hormone
WT1 - Wilms tumor 1 gene
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